Patrick Daly

DocwireNews

In an article in the Journal of Hematology &amp; Oncology, Heng Mei and collaborating researchers reported results from their phase III trial on hetrombopag, a novel thrombopoietin receptor agonist, stating that &ldquo;hetrombopag was superior to placebo in increasing platelet counts and reducing bleeding risk and the use of rescue therapy over the 8-week treatment period in immune thrombocytopenia (ITP) patients with an insufficient response or relapse after prior ITP treatment or splenectomy.&rdquo;The investigators further reported that platelet response was maintained with extended hetrombopag exposure during the 24-week treatment period.The clinical trial enrolled patients with ITP who had failed previous treatment or relapsed. The participants received initial doses of either 2.5 mg or 5 mg hetrombopag, once daily, or a matching placebo. Patients in the placebo group switched to eltrombopag after completing 10 weeks of treatment while the hetrombopag group continued with hetrombopag. The primary outcome of the study was the rate of successful responses after eight weeks, defined as a platelet count of &ge;50&thinsp;&times;&thinsp;109/L.The primary endpoint was achieved by more patients in the 2.5 mg group (58.9%; odds ratio [OR] = 25.97, 95% confidence interval [CI], 9.83&ndash;68.63; p&thinsp;&lt;0.0001) and the 5 mg group (64.3%; OR = 32.81, 95% CI, 12.39&ndash;86.87; p&thinsp;&lt;0.0001), compared with the placebo group (5.9%). Hetrombopag produced more platelet responses and also reduced bleeding risk and use of rescue therapy throughout the treatment period. The most common adverse events at 24 weeks in the hetrombopag group were upper respiratory tract infection (42.2%), urinary tract infection (17.1%), immune thrombocytopenic purpura (17.1%), and hematuria (15%).Overall, the authors reported that &ldquo;hetrombopag was generally well tolerated, with a manageable safety profile,&rdquo; and that &ldquo;an initial dosage of 2.5 mg hetrombopag once daily might be appropriate for Chinese patients with ITP.&rdquo;

Sara Nunnery, MD, MSCI

Trastuzumab Deruxtecan in HER2-Low Breast Cancer: Who’s the Right Patient?

HER2 Breast Cancer

Meghan Sise, MD

Joel M. Topf, MD, FACP

Redefining Carboplatin Dosing

NKF Spring Clinical Meetings 2025

MarkAlain Déry, DO

The Significant Danger Measles Pose for Unvaccinated Children

Infectious Disease

Latest News

Hetrombopag Versus Placebo in the Treatment of Immune Thrombocytopenia

In an article in the Journal of Hematology &amp; Oncology, Heng Mei and collaborating researchers reported results from their phase III trial on hetrombopag, a novel ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe